2026 Global: Biologics Contract Manufacturing-Competitive Review (2032) report
Description
The 2026 Global: Biologics Contract Manufacturing-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Lonza, Basel, Switzerland, is among the largest biologics contract manufacturers, providing end-to-end capabilities from early development to commercial production, including cell culture, microbial processes, purification, and fill-finish, with a network that supports multiple therapeutic modalities. Samsung BioLogics, Incheon, Republic of Korea, operates expansive manufacturing campuses designed for high-volume production of monoclonal antibodies and other biologics, offering integrated services from process development through to commercial-scale manufacturing and labeling. WuXi Biologics, Shanghai, China, runs a globally distributed platform that includes both mammalian and microbial production, process development, analytical testing, and regulatory support, enabling rapid scale-up and biosimilar programs. Thermo Fisher Scientific, Waltham, United States, delivers bioprocessing solutions through its Bioprocessing Solutions segment, including cell culture media, single-use systems, analytical tools, and contract manufacturing services spanning clinical to commercial supply. Catalent, Somerset, United States, operates Catalent Biologics, providing development, formulation, fill-finish, and early-stage manufacturing with a focus on speed, quality, and regulatory readiness.
Boehringer Ingelheim BioXcellence, Ingelheim am Rhein, Germany, operates a global biologics manufacturing network delivering development, optimization, and commercial production for monoclonal antibodies and advanced therapies within a rigorous quality framework. Biocon Biologics, Bengaluru, India, offers a comprehensive biologics CDMO platform with process development, scale-up, and commercial manufacturing of monoclonal antibodies and biosimilars across international markets. Syngene International, Bengaluru, India, provides integrated biopharma services including process development, cGMP manufacturing, and analytical testing for biologics across mammalian and microbial platforms, leveraging an established network to support early-stage programs through late-stage commercialization for global clients. Rentschler Biopharma, Laupheim, Germany, specializes in development and manufacturing of complex biologics, offering cell culture, purification, and fill-finish, with scalable facilities designed to accelerate iterative development and market-ready production. IDT Biologika, Dessau-Roßlau, Germany, provides vaccine and biologics manufacturing services, covering upstream and downstream processing and fill-finish, with emphasis on regulatory compliance and robust quality systems and regulatory excellence.
Together, these ten organizations constitute a globally distributed ecosystem for biologics development and production, enabling rapid transitions from discovery through commercialization while meeting stringent regulatory standards. Their geographic footprints—primarily in Europe, North America, and Asia—provide resilience in supply chains, diversified talent pools, and access to a broad range of platforms, including mammalian cell culture, microbial expression, and advanced purification technologies. Capacity scales span from pilot and mid-scale to commercial manufacturing, supported by analytical development, quality control, regulatory affairs, and fill-finish operations designed to meet biosafety and potency requirements. In response to accelerating biosimilar demand and complex next-generation modalities, these CMOs emphasize speed, technology transfer efficiency, and robust data systems, enabling faster time-to-market with consistent product quality. Collectively, their networks reduce development timelines, increase process flexibility, and sustain supply during public health emergencies, thereby shaping the competitive landscape of global biologics manufacturing and enabling access to innovative therapies worldwide across borders.
Lonza, Basel, Switzerland, is among the largest biologics contract manufacturers, providing end-to-end capabilities from early development to commercial production, including cell culture, microbial processes, purification, and fill-finish, with a network that supports multiple therapeutic modalities. Samsung BioLogics, Incheon, Republic of Korea, operates expansive manufacturing campuses designed for high-volume production of monoclonal antibodies and other biologics, offering integrated services from process development through to commercial-scale manufacturing and labeling. WuXi Biologics, Shanghai, China, runs a globally distributed platform that includes both mammalian and microbial production, process development, analytical testing, and regulatory support, enabling rapid scale-up and biosimilar programs. Thermo Fisher Scientific, Waltham, United States, delivers bioprocessing solutions through its Bioprocessing Solutions segment, including cell culture media, single-use systems, analytical tools, and contract manufacturing services spanning clinical to commercial supply. Catalent, Somerset, United States, operates Catalent Biologics, providing development, formulation, fill-finish, and early-stage manufacturing with a focus on speed, quality, and regulatory readiness.
Boehringer Ingelheim BioXcellence, Ingelheim am Rhein, Germany, operates a global biologics manufacturing network delivering development, optimization, and commercial production for monoclonal antibodies and advanced therapies within a rigorous quality framework. Biocon Biologics, Bengaluru, India, offers a comprehensive biologics CDMO platform with process development, scale-up, and commercial manufacturing of monoclonal antibodies and biosimilars across international markets. Syngene International, Bengaluru, India, provides integrated biopharma services including process development, cGMP manufacturing, and analytical testing for biologics across mammalian and microbial platforms, leveraging an established network to support early-stage programs through late-stage commercialization for global clients. Rentschler Biopharma, Laupheim, Germany, specializes in development and manufacturing of complex biologics, offering cell culture, purification, and fill-finish, with scalable facilities designed to accelerate iterative development and market-ready production. IDT Biologika, Dessau-Roßlau, Germany, provides vaccine and biologics manufacturing services, covering upstream and downstream processing and fill-finish, with emphasis on regulatory compliance and robust quality systems and regulatory excellence.
Together, these ten organizations constitute a globally distributed ecosystem for biologics development and production, enabling rapid transitions from discovery through commercialization while meeting stringent regulatory standards. Their geographic footprints—primarily in Europe, North America, and Asia—provide resilience in supply chains, diversified talent pools, and access to a broad range of platforms, including mammalian cell culture, microbial expression, and advanced purification technologies. Capacity scales span from pilot and mid-scale to commercial manufacturing, supported by analytical development, quality control, regulatory affairs, and fill-finish operations designed to meet biosafety and potency requirements. In response to accelerating biosimilar demand and complex next-generation modalities, these CMOs emphasize speed, technology transfer efficiency, and robust data systems, enabling faster time-to-market with consistent product quality. Collectively, their networks reduce development timelines, increase process flexibility, and sustain supply during public health emergencies, thereby shaping the competitive landscape of global biologics manufacturing and enabling access to innovative therapies worldwide across borders.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
